 September 29, 2014 Allergan Perspective on Valeant Pharmaceuticals International, Inc. Sales Growth Numbers Exhibit 99.1 |
 Important Information Information contained in this presentation regarding Valeant Pharmaceuticals International, Inc. (“Valeant”) is taken directly from the information publicly disclosed by Valeant and we do not make any representations or warranties, either express or implied, with respect to such information’s accuracy or completeness. In addition, certain other information contained in this presentation is based on publicly available sources as of the date of this presentation, and while we have no reason to believe that such information is not accurate, we can provide no such assurances with respect thereto. This presentation was prepared with the assistance of Allergan’s independent financial consultants and forensic accountants, Alvarez & Marsal and FTI Consulting. The information in this presentation represents the opinions of Allergan and investors and stockholders should make their own independent investigations of the matters referenced in this presentation and draw their own conclusions. 2 |
 Perspective on Valeant’s Sales Growth Numbers • On September 24, 2014, Valeant provided an update on third quarter 2014 results • Q3 2014 growth numbers provided by Valeant should be viewed in perspective of their Q3 2013 results 3 |
 Valeant Quarterly Sales Growth All data verified by forensic accountants. All data from Valeant public filings. Figures not adjusted for currency or divestitures. Results for all periods include divested Injectable business. Represents product sales only and is on a pro forma basis. Bausch & Lomb Q1’12, Q2’12, Q1’13, Q2’13 from Bausch & Lomb financial statements included in VRX 6/10/13 and 10/21/13 8Ks. Q3’13 amount derived from subtracting other three quarters from FY13 amount per slide 150 of Valeant 5/28/14 presentation. Q3’12 amount derived from subtracting other three quarters from FY12 amount per Bausch & Lomb audited financial statements. 1 Based on Sept. 24, 2014 Valeant press release YOY Growth Q1’13 Q2’13 Q3’13 Q4’13 Q1’14 Q2’14 Q3’14¹ Total Valeant (excluding Generics) 1% 5% -3% 8% 1% 7% Total Valeant 5% 6% -9% 4% -1% 4% 15% Impact of Generics on Total Valeant Growth 4% 1% -6% -4% -2% -3% 4 Q3’14 growth positively affected by a weak Q3’13 (B&L acquisition on August 6, 2013) |
 Bausch & Lomb Quarterly Sales All data verified by forensic accountants. All data from Valeant public filings. Bausch & Lomb Q1’12, Q2’12, Q1’13, Q2’13 from Bausch & Lomb financial statements included in VRX 6/10/13 and 10/21/13 8Ks. Q3’13 amount derived from subtracting other three quarters from FY13 amount per slide 150 of Valeant 5/28/14 presentation. Q3’12 amount derived from subtracting other three quarters from FY12 amount per Bausch & Lomb audited financial statements.Figures not adjusted for currency or divestitures. 1 Based on Sept. 24, 2014 Valeant press release 2 Calculated using 10% Q3’14 Bausch & Lomb update as provided by Valeant on Sept. 24, 2014 over Q3’13 actual sales dollars. 5 • Q3’14 growth positively affected by a weak Q3’13 (B&L acquisition on August 6, 2013) • Q4’14 YOY growth will be against a more difficult comparable (Q4’13) |
 Important Information Allergan, its directors and certain of its officers and employees are participants in solicitations of Allergan stockholders. Information regarding the names of Allergan's directors and executive officers and their respective interests in Allergan by security holdings or otherwise is set forth in Allergan's proxy statement for its 2014 annual meeting of stockholders, filed with the SEC on March 26, 2014, as supplemented by the proxy information filed with the SEC on April 22, 2014. Additional information can be found in Allergan's Annual Report on Form 10-K for the year ended December 31, 2013, filed with the SEC on February 25, 2014 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, filed with the SEC on August 5, 2014. To the extent holdings of Allergan's securities have changed since the amounts printed in the proxy statement for the 2014 annual meeting of stockholders, such changes have been reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. These documents are available free of charge at the SEC’s website at www.sec.gov. STOCKHOLDERS ARE ENCOURAGED TO READ ANY ALLERGAN PROXY STATEMENT (INCLUDING ANY SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT ALLERGAN MAY FILE WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders will be able to obtain, free of charge, copies of any proxy statement and any other documents filed by Allergan with the SEC at the SEC's website at www.sec.gov. In addition, copies will also be available at no charge at the Investors section of Allergan's website at www.allergan.com. 6 |
 September 29, 2014 Allergan Perspective on Valeant Pharmaceuticals International, Inc. Sales Growth Numbers |